A5057779932- Cytomegalovirus and herpesvirus research
- Herpesvirus Infections and Treatments
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Transplantation: Methods and Outcomes
- Influenza Virus Research Studies
- Respiratory viral infections research
- Polyomavirus and related diseases
- Renal Transplantation Outcomes and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Antifungal resistance and susceptibility
- Hepatitis B Virus Studies
- COVID-19 Impact on Reproduction
- Mycobacterium research and diagnosis
- Immune Cell Function and Interaction
- Hepatitis C virus research
- Immunotherapy and Immune Responses
- Viral-associated cancers and disorders
- Viral gastroenteritis research and epidemiology
- Organ Transplantation Techniques and Outcomes
- Parvovirus B19 Infection Studies
- Long-Term Effects of COVID-19
- Fungal Infections and Studies
- Liver Disease and Transplantation
- Tuberculosis Research and Epidemiology
University Health Network
2016-2025
Toronto General Hospital
2014-2025
University of Toronto
2016-2025
Toronto General Hospital Research Institute
2025
All India Institute of Medical Sciences Rishikesh
2022-2024
All India Institute of Medical Sciences Raipur
2024
All India Institute of Medical Sciences Bhopal
2024
George Institute for Global Health
2023
University College London
2023
Apollo Hospitals
2023
Despite recent advances, cytomegalovirus (CMV) infections remain one of the most common complications affecting solid organ transplant recipients, conveying higher risks complications, graft loss, morbidity, and mortality. Research in field development prior consensus guidelines supported by The Transplantation Society has allowed a more standardized approach to CMV management. An international multidisciplinary panel experts was convened expand revise evidence expert opinion-based on...
Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in randomized, double-blind, noninferiority trial of treatment for invasive candidiasis.
Cytomegalovirus (CMV) continues to be one of the most common infections after solid-organ transplantation, resulting in significant morbidity, graft loss, and adverse outcomes. Management CMV varies considerably among transplant centers but has been become more standardized by publication consensus guidelines Infectious Diseases Section The Transplantation Society. An international panel experts was reconvened October 2012 revise expand evidence expert opinion-based on management, including...
Abstract These updated guidelines of the AST IDCOP review vaccination solid organ transplant candidates and recipients. General principles as well use specific vaccines in this population are discussed. Vaccination should be reviewed pre‐transplant setting appropriate updated. Both inactivated live can given pre‐transplant. The timing post‐transplant taken into account. In setting, administered starting at 3 months with exception influenza which early one month. Inactivated safely...
Transplant candidates and recipients are at increased risk of infectious complications vaccine-preventable diseases. Every effort should be made to ensure that transplant candidates, their household members healthcare workers have completed the full complement recommended vaccinations prior transplantation. Since response many vaccines is diminished in organ failure, immunized early course disease. It vaccination status ideally documented pretransplant clinic visit patient referred for...
The COVID-19 pandemic has rapidly evolved and changed our way of life in an unprecedented manner. emergence impacted transplantation worldwide. impact not been just restricted to issues pertaining donors or recipients, but also health-care resource utilization as the intensity cases certain jurisdictions exceeds available capacity. Here we provide a personal viewpoint representing different from around world order outline current on organ transplantation. Based collective experience, discuss...
To date, only monoclonal antibodies have been shown to be effective for outpatients with COVID-19. Interferon lambda-1 is a type III interferon involved in innate antiviral responses activity against respiratory pathogens. We aimed investigate the safety and efficacy of peginterferon lambda treatment mild-to-moderate COVID-19.In this double-blind, placebo-controlled trial, laboratory-confirmed COVID-19 were randomly assigned single subcutaneous injection 180 μg or placebo within 7 days...
Therapies for refractory cytomegalovirus infections (with or without resistance [R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti-cytomegalovirus activity through the inhibition of UL97 protein kinase. In this phase 3, open-label study, hematopoietic-cell and solid-organ with R/R were randomized 2:1 to maribavir 400 mg twice daily investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, cidofovir) 8 weeks, 12 weeks follow-up. The...
The recent identification of an outbreak 2019- novel Coronavirus is currently evolving, and the impact on transplantation unknown. However, it imperative that we anticipate potential transplant community in order to avert severe consequences this infection both contacts patients.
Solid organ transplant recipients are at high risk of severe disease from COVID-19. We assessed the immunogenicity mRNA-1273 vaccine using a combination antibody testing, surrogate neutralization assays, and T cell assays. Patients were immunized with two doses after each dose above tests. CD4+ CD8+ responses in subset flow-cytometry. A total 127 patients enrolled which 110 provided serum all time points. positive anti-RBD was seen 5.0% one 34.5% doses. Neutralizing present 26.9%. Of note,...
On June 3, 2023, the American Society of Transplant Surgeons convened a meeting in San Diego, California to (1) develop consensus statement with supporting data on ethical tenets thoracoabdominal normothermic regional perfusion (NRP) and abdominal NRP; (2) provide guidelines for standards practice that should govern NRP (3) implement central database collection donor recipient United States. National international leaders fields neuroscience, transplantation, critical care, NRP, Organ...
Data regarding coronavirus disease 2019 (COVID-19) outcomes in solid organ transplant recipients (SOTr) across severe acute respiratory syndrome 2 (SARS-CoV-2) waves, including the impact of different measures, are lacking. This cohort study, conducted from March 2020 to May 2023 Toronto, Canada, aimed analyze COVID-19 1975 SOTr various SARS-CoV-2 waves and assess preventive treatment measures. The primary outcome was COVID-19, defined as requiring supplemental oxygen, with secondary...
Late-onset cytomegalovirus (CMV) disease commonly occurs after discontinuation of antiviral prophylaxis. We determined the utility testing CD8+ T-cell response against CMV as a predictor late-onset standard course Transplant patients at high-risk for were enrolled. T-cell-mediated immunity (CMI) was tested using QuantiFERON-CMV assay baseline, 1, 2 and 3 months posttransplant by measurement interferon-gamma to whole blood stimulation with 21-peptide pool. The primary outcome ability CMI...
Transplant candidates and recipients are at increased risk of infectious complications. Every effort should be made to ensure that transplant candidates, their household members healthcare workers have completed the full complement recommended vaccinations prior transplantation. Since response many vaccines is diminished in organ failure, immunized early course disease. It vaccination status reviewed time first clinic visit, a vaccine strategy developed once again patient listed for While...
Community-acquired respiratory viral infections (RVIs) are common in lung transplant patients and may be associated with acute rejection bronchiolitis obliterans syndrome (BOS). The use of sensitive molecular methods that can simultaneously detect a large panel viruses help better define their effects.Lung recipients undergoing serial surveillance diagnostic bronchoalveolar lavages (BALs) during period 3 years were enrolled. BAL samples underwent multiplex testing for 19 types/subtypes using...
The annual standard-dose (SD) influenza vaccine has suboptimal immunogenicity in solid organ transplant recipients (SOTRs). Influenza that contains higher doses of antigens may lead to greater this population.We conducted a randomized, double-blind trial compare the safety and 2016-2017 high-dose (HD; FluzoneHD, Sanofi) vs SD (Fluviral, GSK) adult SOTRs. Preimmunization 4-week postimmunization sera underwent strain-specific hemagglutination inhibition assay.We enrolled 172 patients who...
Seasonal influenza infection may cause significant morbidity and mortality in transplant recipients. The purpose of this study was to assess the epidemiology symptomatic posttransplant determine risk factors for severe disease.Twenty centers United States, Canada, Spain prospectively enrolled solid organ (SOT) or hematopoietic stem cell (HSCT) recipients with microbiologically confirmed influenza over 5 consecutive years (2010-2015). Demographics, microbiology data, outcomes were collected....